SG Americas Securities LLC Lowers Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

SG Americas Securities LLC trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 66.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 6,978 shares of the company’s stock after selling 13,575 shares during the quarter. SG Americas Securities LLC’s holdings in Mirum Pharmaceuticals were worth $289,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $189,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $215,000. Creative Planning bought a new position in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $249,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Mirum Pharmaceuticals by 65.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,176 shares of the company’s stock valued at $358,000 after acquiring an additional 3,639 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on MIRM shares. Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup raised their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Leerink Partners boosted their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Price Performance

MIRM opened at $52.28 on Thursday. The firm has a 50-day moving average price of $44.49 and a 200-day moving average price of $42.10. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $53.49. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of -25.88 and a beta of 0.96.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.57) EPS. Equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current year.

Insider Activity at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 1,998 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $85,554.36. Following the completion of the transaction, the chief operating officer now directly owns 27,015 shares in the company, valued at $1,156,782.30. The trade was a 6.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Peetz sold 9,102 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the sale, the chief executive officer now owns 115,920 shares in the company, valued at $5,589,662.40. This trade represents a 7.28 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,415 shares of company stock worth $2,015,670. 22.87% of the stock is owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.